HealthQuest, Warsaw, Poland.
Decision Analysis and Support Unit, SGH Warsaw School of Economics, Warsaw, Poland.
BMC Health Serv Res. 2020 Jun 17;20(1):552. doi: 10.1186/s12913-020-05411-2.
Dysphagia is a well-known stroke complication characterised by difficulty in swallowing. It may affect the majority of stroke patients and increases mortality and morbidity, due to aspiration pneumonia and malnutrition. Food thickening may help patients to feed themselves, and its effectiveness was demonstrated. However, the cost-effectiveness studies are lacking. We evaluate the cost-utility of xanthan gum-based consistency modification therapy (Nutilis Clear®) in adult post-stroke patients from the public payer perspective in Poland.
Routine clinical practice was used as a comparator, as no alternative specific treatment for dysphagia is available. To verify the robustness of the results against the modelling approach, we built two models: a static (a fixed simple-equations model, 8-week time horizon of dysphagia) and a dynamic one (Markov model, with a possible dysphagia resolution over a 1-year horizon). In both models, the treatment costs, health state utilities, and clinical events (i.e. aspiration, aspiration pneumonia, death) were included. Parameters were estimated jointly for both models, except for the duration of dysphagia and the risk of aspiration pneumonia (specific to the time horizon). We only assumed Nutilis Clear® to prevent aspirations, without affecting dysphagia duration.
The average cost of one quality-adjusted life year (i.e. the incremental cost-utility ratios, ICURs) amounted to 21,387 PLN (€1 ≈ 4.5 PLN), and 20,977 PLN in static and dynamic model, respectively; far below the cost-effectiveness threshold in Poland (147,024 PLN). The one-way, scenario, and probabilistic sensitivity analysis confirmed these findings.
Nutilis Clear® is highly cost-effective in Poland from the public payer perspective. Our approach can be used in other countries to study the cost-effectiveness of food thickening in stroke patients.
吞咽困难是一种众所周知的中风并发症,其特征是吞咽困难。由于吸入性肺炎和营养不良,它可能会影响大多数中风患者,并增加死亡率和发病率。食物增稠可以帮助患者进食,其有效性已得到证实。然而,缺乏成本效益研究。我们从波兰公共支付者的角度评估了基于黄原胶的一致性改性治疗(Nutilis Clear®)在成年中风后患者中的成本-效用。
常规临床实践被用作对照,因为没有针对吞咽困难的替代特定治疗方法。为了验证模型方法的稳健性,我们构建了两个模型:静态模型(一个固定的简单方程模型,吞咽困难的 8 周时间范围)和动态模型(Markov 模型,在 1 年的时间范围内可能解决吞咽困难)。在这两个模型中,都包括了治疗成本、健康状态效用和临床事件(即吸入、吸入性肺炎、死亡)。参数是针对两个模型共同估计的,除了吞咽困难的持续时间和吸入性肺炎的风险(特定于时间范围)。我们仅假设 Nutilis Clear®可预防吸入,而不影响吞咽困难的持续时间。
一个质量调整生命年的平均成本(即增量成本-效用比,ICUR)为 21,387 波兰兹罗提(€1≈4.5 波兰兹罗提),静态和动态模型分别为 20,977 波兰兹罗提;远低于波兰的成本效益阈值(147,024 波兰兹罗提)。单向、情景和概率敏感性分析证实了这些发现。
从波兰公共支付者的角度来看,Nutilis Clear®在波兰具有很高的成本效益。我们的方法可用于其他国家,以研究中风患者食物增稠的成本效益。